GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellSource Co Ltd (TSE:4880) » Definitions » EV-to-EBIT

CellSource Co (TSE:4880) EV-to-EBIT : 18.70 (As of Jun. 04, 2024)


View and export this data going back to 2019. Start your Free Trial

What is CellSource Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CellSource Co's Enterprise Value is 円20,826 Mil. CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was 円1,114 Mil. Therefore, CellSource Co's EV-to-EBIT for today is 18.70.

The historical rank and industry rank for CellSource Co's EV-to-EBIT or its related term are showing as below:

TSE:4880' s EV-to-EBIT Range Over the Past 10 Years
Min: 15.09   Med: 71.31   Max: 301.97
Current: 18.7

During the past 7 years, the highest EV-to-EBIT of CellSource Co was 301.97. The lowest was 15.09. And the median was 71.31.

TSE:4880's EV-to-EBIT is ranked worse than
65.18% of 425 companies
in the Biotechnology industry
Industry Median: 10.2 vs TSE:4880: 18.70

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CellSource Co's Enterprise Value for the quarter that ended in Jan. 2024 was 円20,058 Mil. CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 was 円1,114 Mil. CellSource Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 was 5.55%.


CellSource Co EV-to-EBIT Historical Data

The historical data trend for CellSource Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellSource Co EV-to-EBIT Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-EBIT
Get a 7-Day Free Trial 47.14 122.23 116.78 49.88 24.64

CellSource Co Quarterly Data
Oct18 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.60 25.46 22.75 24.64 18.01

Competitive Comparison of CellSource Co's EV-to-EBIT

For the Biotechnology subindustry, CellSource Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellSource Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellSource Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CellSource Co's EV-to-EBIT falls into.



CellSource Co EV-to-EBIT Calculation

CellSource Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20826.036/1113.592
=18.70

CellSource Co's current Enterprise Value is 円20,826 Mil.
CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellSource Co  (TSE:4880) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CellSource Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2024 ) =EBIT / Enterprise Value (Q: Jan. 2024 )
=1113.592/20058.3125
=5.55 %

CellSource Co's Enterprise Value for the quarter that ended in Jan. 2024 was 円20,058 Mil.
CellSource Co's EBIT for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,114 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CellSource Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CellSource Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


CellSource Co (TSE:4880) Business Description

Traded in Other Exchanges
N/A
Address
Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.

CellSource Co (TSE:4880) Headlines

No Headlines